Cannabinoid Combo Therapy Ended Teen’s Bowel Disease Symptoms, Study Reports

Cannabinoid Combo Therapy Ended Teen’s Bowel Disease Symptoms, Study Reports
A 13-year-old boy whose Crohn’s disease and colitis had failed to respond to standard treatments became symptom-free with a combo therapy that included cannabinoids, the cannabinoid therapy maker Vitality Biopharma reported. The study is one of the first to show that cannabinoids can eliminate inflammatory bowel disease (IBD) symptoms in a child or young adult resistant to other therapies, the company said. The research, “Induction of Remission in Drug-Resistant Pediatric Inflammatory Bowel Disease with Cannabinoid Therapy,” has yet to be published in a medical journal. The boy received medical cannabis under California’s Compassionate Use Act. Vitality played no role in the treatment, according to a press release. The boy was diagnosed at age 9 with Crohn's disease and mild-to-moderate colitis, and was hospitalized on several occasions. He had a poor appetite, which led to weight loss and stunted growth, and failed to respond to conventional IBD treatments. Although he did respond initially to the TNF-α inhibitor Remicade (infliximab), it failed to help after a few weeks. "Temporary symptomatic benefit was observed, but quickly dissipated," the researchers reported. His level of calprotectin -- a sign of bowel disease in children -- rose again despite treatment throughout 2015. Improvements in calprotectin level suggest disease-modifying activity as well as symptom relief, the researchers noted. In February 2016, the boy started taking a combination of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) three times a day. The 3-mg doses of each therapy turned him around, researchers said. "The patient and family reported almost immediate symptomatic improvement, with increased appetite and body weight, reduced inflammatory sco
Subscribe or to access all post and page content.